A Comparative Study of Chinese and American Orange Books Based on the 5W Model

doi:10.19803/j.1672-8629.2021.09.02

Abstract

Abstract: Objective To compare the similarities and differences between the Chinese and American Orange Books from the perspective of communication in order to contribute to the improvement of the Chinese Orange Book. Methods The 5W model, which was the classic theoretical model in the field of communication, was used. The related factors were divided into Who, Says What, In Which Channel, To Whom and with What Effect. Through literature research, the differences in various factors of communication between Chinese and American Orange Books were analyzed. Results There was some gap in management organizations, content, distribution channels, audience and effectiveness between the American Orange Book and the Chinese Orange Book. Conclusion It is recommended that the Chinese Orange Book be updated in line with the current drug supervision in China and by learning from the American Orange Book.

Key words: Orange Book, 5W model, comparative study, suggestions for improvement

CLC Number:

R954

LI Yiyun, LIAO Caiyun, PAN Jing, WEN Baoshu. A Comparative Study of Chinese and American Orange Books Based on the 5W Model[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 806-809.

References

[1] Chen ML.The mechanism of government communication[J]. Journal of Peking University(Philosophy and Social Sciences(北京大学学报(哲学社会科学版)), 2004(2): 133-139.
[2] Lasswell H.The structure and function of communication in society(社会传播的结构与功能)[M]. Beijing: Communication University of China Press, 2013.
[3] Food and Drug Administration. Therapeutically equivalent drugs[J]. Federal Register, 1979, 44(9): 2932-2953.
[4] Food and Drug Administration. Listing of patent information in the orange book; establishment of a public docket; request for comments[J]. U.S. Food & Drug Administration Documents/Find, 2020, 85(105): 33169-33173.
[5] Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations (Orange Book); establishment of a public docket; request for comments[J]. U.S. Food & Drug Administration Documents/Find, 2020, 85(105): 33165-33167.
[6] Food and Drug Administration. Orange book-questions and answers; draft guidance for industry[J]. U.S. Food & Drug Administration Documents/Find, 2020, 85(105): 33167-33169.
[7] The General Office of the Central Committee. The General Office of the State Council issued the“Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices”[J]. Bulletin of the State Council of the People’s Republic of China(中华人民共和国国务院公报), 2017(29): 39-44.
[8] National Medical Products Administration. Announcement of the general administration on issuing the catalogue of listed drugs in China (No. 172 of 2017) [EB/OL].(2017-12-28)[2021-03-01]. http://list.cde.org.cn/news/detail?id=5.
[9] Guo QG.A course in communication, 2nd edition(传播学教程(第2版))[M]. Beijing: China Renmin University Press, 2011.
[10] Inside Washington Publishers.FDA no longer printing orange book after this year[J]. Inside Washington’s FDA Week, 2004, 10(45): 8-9.
[11] Office of the Federal Register, National Archives and Records Administration. Federal Register Volume 45, Issue 213 [EB/OL] (1980-10-31)[2021-03-01]. https://www.govinfo.gov/content/pkg/FR-1980-10-31/pdf/FR-1980-10-31.pdf.
[12] Alruthia Y, Aljohani B, Alsharif WR, et al.Prospects of establishing a saudi version of the United States Food and Drug Administration Orange Book[J]. Health Policy and Technology, 2020, 10(1): 120-125.
[13] Parker RE, Martinez DR, Covington TR.Drug product selection-Part 3: The Orange Book[J]. American Pharmacy, 1991, 31(9): 47-56.
[14] Brushwood DB.Pharmaco-legal considerations in the clinical use of decongestants[J]. Pharmacotherapy the Journal of Human Pharmacology & Drug Therapy, 2012, 13(6P2): 135S-146S.
[15] Millaar TP, Wong S, Odierna DH, et al.Applying the essential medicines concept to US preferred drug lists[J]. American Journal of Public Health, 2011, 101(8): 1444-1448.
[16] Young AK, Andrus MS.Pharmaceutical pricing and Hatch-Waxman reform: the right prescription[J]. Journal of Generic Medicines, 2004, 1(3): 228-237.
[17] Liu YT.China’s drug innovation system has taken a solid step. The first Catalogue of Listed Drugs in China was released[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2018(1): 5-7.